|
Delaware
|
| |
2834
|
| |
47-1178401
|
|
|
(State or other jurisdiction of
incorporation or organization) |
| |
(Primary Standard Industrial
Classification Code Number) |
| |
(I.R.S. Employer
Identification Number) |
|
|
Donald R. Reynolds
S. Halle Vakani Lorna A. Knick Wyrick Robbins Yates & Ponton LLP 4101 Lake Boone Trail, Suite 300 Raleigh, NC 27607 (919) 781-4000 |
| |
Darrick M. Mix
Jonathan Cohen Duane Morris LLP 30 South 17th Street Philadelphia, PA 19103-4196 (215) 979-1000 |
|
| Large accelerated filer ☐ | | | | | | Accelerated filer ☐ | |
| Non-accelerated filer ☒ | | | | | | Smaller reporting company ☒ | |
| | | | | | | Emerging growth company ☒ | |
| | ||||||||||||||||||||||||||||
Title of each class of securities to be registered
|
| | |
Amounts to be
Registered(1) |
| | |
Proposed
Maximum Offering Price Per Share(2) |
| | |
Proposed Maximum
Aggregate Offering Price(1)(2) |
| | |
Amount of
Registration Fee |
| ||||||||||||
Common stock, $0.0001 par value per share
|
| | | | | 1,380,000 | | | | | | $ | 3.984 | | | | | | $ | 5,497,920.00 | | | | | | $ | 666.35 | | |
|
| | |
Per Share
|
| |
Total
|
| ||||||
Public offering price
|
| | | $ | | | | | $ | | | ||
Underwriting discounts(1)
|
| | | $ | | | | | | $ | | | |
Proceeds to us, before expenses(2)
|
| | | $ | | | | | | $ | | | |
| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 1 | | | |
| | | | 2 | | | |
| | | | 11 | | | |
| | | | 12 | | | |
| | | | 14 | | | |
| | | | 16 | | | |
| | | | 17 | | | |
| | | | 18 | | | |
| | | | 21 | | | |
| | | | 24 | | | |
| | | | 24 | | | |
| | | | 24 | | | |
| | | | 25 | | |
|
Product Candidate
|
| |
Indication
|
| |
Next Expected Milestones
|
|
|
MicroStat
|
| |
Mydriasis (Pupil Dilation)
|
| |
Report Phase III Trial Results H1 2019
|
|
|
MicroPine
|
| |
Pediatric Myopia Progression (Near Sightedness)
|
| |
Initiate Phase III Trial H1 2019
|
|
|
MicroProst
|
| |
Chronic Angle Closure Glaucoma
|
| |
Initiate Phase III Trial H1 2019
|
|
|
MicroTears
|
| |
Dry Eye
|
| |
OTC Registration H1 2019
|
|
|
Assumed public offering price per share
|
| | | | | | | | | $ | 4.00 | | |
|
Historical net tangible book value per share as of September 30, 2018
|
| | | $ | 1.96 | | | | | | | | |
|
Increase in net tangible book value per share attributable to this offering
|
| | | $ | 0.15 | | | | | | | | |
|
As adjusted tangible book value per share, after giving effect to this offering
|
| | | | | | | | | $ | 2.11 | | |
|
Dilution per share to investors in this offering
|
| | | | | | | | | $ | 1.89 | | |
| | | | | | | | |
Total
|
| |||||||||
| | |
Per
Share |
| |
Without
Exercise of Option to Purchase Additional Common Shares |
| |
With Exercise
of Option to Purchase Additional Common Shares |
| |||||||||
Underwriting discount for common stock to be paid by us
(7%) |
| | | $ | | | | | $ | | | | | $ | | |
| | |
Amount
to be paid |
| |||
SEC registration fee
|
| | | $ | 666.35 | | |
FINRA filing fee
|
| | | | 1,550 | | |
Transfer agent and registrar fees
|
| | | | 5,000 | | |
Accounting fees and expenses
|
| | | | 67,000 | | |
Legal fees and expenses
|
| | | | 260,000 | | |
Printing and engraving expenses
|
| | | | 35,000 | | |
Miscellaneous
|
| | | | 9,783.65 | | |
Total
|
| | | $ | 379,000 | | |
|
Signature
|
| |
Title
|
| |
Date
|
|
/s/ Tsontcho Ianchulev
Tsontcho Ianchulev
|
| |
Chief Executive Officer
(principal executive officer) and Director |
| |
December 12, 2018
|
|
/s/ John Gandolfo
John Gandolfo
|
| |
Chief Financial Officer
(principal financial and accounting officer) |
| |
December 12, 2018
|
|
/s/ Fredric N. Eshelman
Fredric N. Eshelman
|
| |
Chairman of the Board and Director
|
| |
December 12, 2018
|
|
/s/ Curt H. LaBelle
Curt H. LaBelle
|
| |
Director
|
| |
December 12, 2018
|
|
/s/ Kenneth B. Lee, Jr.
Kenneth B. Lee, Jr.
|
| |
Director
|
| |
December 12, 2018
|
|
/s/ Ernest Mario
Ernest Mario
|
| |
Director
|
| |
December 12, 2018
|
|
/s/ Charles E. Mather IV
Charles E. Mather IV
|
| |
Director
|
| |
December 12, 2018
|
|
/s/ Anthony Y. Sun
Anthony Y. Sun
|
| |
Director
|
| |
December 12, 2018
|
|
/s/ Shuhei Yoshida
Shuhei Yoshida
|
| |
Director
|
| |
December 12, 2018
|
|